Overview

This trial is active, not recruiting.

Conditions colon cancer, rectal cancer
Treatments floxuridine, oxaliplatin, cpt-11
Phase phase 1
Sponsor Memorial Sloan Kettering Cancer Center
Collaborator University of Medicine and Dentistry of New Jersey
Start date August 2000
End date August 2016
Trial size 72 participants
Trial identifier NCT00695201, 00-011

Summary

The purpose of this study is to see how well patients tolerate the side effects of treatment with Floxuridine, Oxaliplatin and Irinotecan. We also want to know if these methods used together are a useful way of treating cancer. We have studied these drugs and know the best doses of each when they are used alone. We do not yet know how well the drugs work with each other. This study will tell us the best doses of each drug when they are given over the same period of time.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
Patients will undergo pump placement and biopsy of diseased liver tissue. Chemotherapy will be initiated as soon as possible following verification of adequate pump placement and perfusion by radiographic pump study. Treatment will continue indefinitely unless a patient experiences a treatment endpoint.
floxuridine, oxaliplatin, cpt-11
For patients on the 4-week cycle: On the first day of each cycle, the pump will be filled with FUDR and dexamethasone. The pump will be emptied of drugs after 2 weeks (on day 15 of each cycle) and filled with heparin (which is used to prevent blood from clotting) and saline. Whether the pump contains drug or heparin and saline, it will need to be emptied and refilled about every two weeks. We will inject either the drugs or the saline and heparin into the pump through the skin using a needle and syringe. In summary, 2 weeks of drug in the pump is followed by 2 weeks without drug in the pump. The systemic chemotherapy (Oxaliplatin/CPT-11) will be administered on the same day as the pump is filled and emptied, ie. Day 1 and Day 15 of each cycle.
(Experimental)
Patients will undergo pump placement and biopsy of diseased liver tissue. Chemotherapy will be initiated as soon as possible following verification of adequate pump placement and perfusion by radiographic pump study. Treatment will continue indefinitely unless a patient experiences a treatment endpoint.
floxuridine, oxaliplatin, cpt-11
For patients on the 5-week cycle: On the first day of each cycle, the pump will be filled with FUDR and dexamethasone. The pump will be emptied of drugs after 2 weeks (on day 15 of each cycle) and filled with heparin and saline. This is repeated on day 29 of each cycle). In summary, 2 weeks of drug in the pump are followed by 3 weeks without drug in the pump. The systemic chemotherapy (Oxaliplatin/CPT-11) will be administered on the same day that the pump is emptied and filled with heparin and saline, i.e. Day 15 and Day 29 of each cycle.

Primary Outcomes

Measure
Determine the MTD of hepatic arterial floxuridine (FUDR) & dexamethasone (Dex) given via implanted pump in combination w biweekly intravenous Oxaliplatin + systemic irinotecan (CPT-11) in patients w unresectable hepatic metastases from colorectal cancer.
time frame: conclusion of the study

Secondary Outcomes

Measure
To determine the preliminary anti-tumor activity of the aforementioned combination chemotherapy.
time frame: conclusion of the study
To procure normal and disease liver tissue for evaluation of TS, p53, p21, TOPO 1, DPD, and ERCC levels.
time frame: conclusion of the study

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - History of histologically confirmed colorectal adenocarcinoma metastatic to the liver with no clinical or radiographic evidence of extrahepatic disease. Confirmation of diagnosis must be performed at MSKCC. - Patient's liver metastases must be deemed unresectable and comprise <70% of the liver parenchyma. - A patient may have had prior chemotherapy or be previously untreated. - Patient may not have received prior treatment with FUDR or >2 doses of Oxaliplatin. - KPS > or = to 60%. - WBC > or = to 3,000 cells/mm3 and platelet count > or = to 100,000 cells/mm3 within 14 days of registration. - Creatinine < or = to 1.5 mg/dl within 14 days of registration. - Total serum bilirubin < or = 2.0 mg/dl within 14 days of registration. Exclusion Criteria: - No active concurrent malignancies: except a patient's potentially resectable colorectal primary. - Patient must not have obstruction of GI or GU tract. - Patient must not have current, symptomatic peripheral sensory neuropathy. - No prior radiation to liver. - No active infection, ascites, or hepatic encephalopathy. - Age ≥ 18 years. - Female patients cannot be pregnant or lactating. - Signed informed consent.

Additional Information

Official title A Phase I Study of Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Intravenous Oxaliplatin Plus Irinotecan in Patients With Unresectable Hepatic Metastases From Colorectal Cancer.
Principal investigator Nancy Kemeny, MD
Trial information was received from ClinicalTrials.gov and was last updated in September 2015.
Information provided to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center.